{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:12:26Z","timestamp":1768878746652,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","award":["CTPS_08_18"],"award-info":[{"award-number":["CTPS_08_18"]}],"id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00280-018-3683-8","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T04:23:16Z","timestamp":1536639796000},"page":"887-898","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4846-7238","authenticated-orcid":false,"given":"Z.","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Seddon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"McCowage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Underhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Cranswick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zacharin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Herschtal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sivasuthan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"3683_CR1","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1634\/theoncologist.11-6-590","volume":"11","author":"A Bleyer","year":"2006","unstructured":"Bleyer A, Viny A, Barr R (2006) Cancer in 15- to 29-year-olds by primary site. Oncologist 11:590\u2013601","journal-title":"Oncologist"},{"key":"3683_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43\u201366","journal-title":"CA Cancer J Clin"},{"key":"3683_CR3","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1016\/j.ejca.2003.09.013","volume":"39","author":"K Albritton","year":"2003","unstructured":"Albritton K, Bleyer WA (2003) The management of cancer in the older adolescent. Eur J Cancer 39:2584\u20132599","journal-title":"Eur J Cancer"},{"key":"3683_CR4","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0031-3955(02)00035-4","volume":"49","author":"A Bleyer","year":"2002","unstructured":"Bleyer A (2002) Older adolescents with cancer in North America deficits in outcome and research. Pediatr Clin North Am 49:1027\u20131042","journal-title":"Pediatr Clin North Am"},{"key":"3683_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cppeds.2005.02.001","volume":"35","author":"A Bleyer","year":"2005","unstructured":"Bleyer A (2005) The adolescent and young adult gap in cancer care and outcome. Curr Probl Pediatr Adolesc Health Care 35:182\u2013217","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"3683_CR6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5694\/j.1326-5377.2004.tb05799.x","volume":"180","author":"AE Mitchell","year":"2004","unstructured":"Mitchell AE et al (2004) Cancer in adolescents and young adults: treatment and outcome in Victoria. Med J Aust 180:59\u201362","journal-title":"Med J Aust"},{"key":"3683_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/ijc.24376","volume":"125","author":"KK Khamly","year":"2009","unstructured":"Khamly KK, Thursfield VJ, Fay M, Desai J, Toner GC, Choong PF, Ngan SY, Powell GJ, Thomas DM (2009) Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer 125:426\u2013431","journal-title":"Int J Cancer"},{"key":"3683_CR8","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2005.205.60","volume":"23","author":"B Klimm","year":"2005","unstructured":"Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A (2005) Role of hematotoxicity and sex in patients with Hodgkin\u2019s lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol 23:8003\u20138011","journal-title":"J Clin Oncol"},{"key":"3683_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/02841860500519760","volume":"45","author":"G Bacci","year":"2006","unstructured":"Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F (2006) Prognostic factors in non-metastatic Ewing\u2019s sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 45:469\u2013475","journal-title":"Acta Oncol"},{"key":"3683_CR10","first-page":"273","volume":"56","author":"EA Gehan","year":"1981","unstructured":"Gehan EA, Nesbit ME Jr, Burgert EO Jr, Viettit J, Tefft M, Perez CA, Kissane J, Hempel C. (1981) Prognostic factors in children with Ewing\u2019s sarcoma. Natl Cancer Inst Monogr 56:273\u2013278","journal-title":"Natl Cancer Inst Monogr"},{"key":"3683_CR11","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1200\/JCO.2012.43.8598","volume":"31","author":"M Collins","year":"2013","unstructured":"Collins M et al (2013) Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol 31:2303\u20132312","journal-title":"J Clin Oncol"},{"key":"3683_CR12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0959-8049(02)00747-5","volume":"39","author":"S Smeland","year":"2003","unstructured":"Smeland S, Muller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, Stenwig AE, Willen H, Holmstrom T, Folleras G, Brosjo O, Kivioja A et al (2003) Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39:488\u2013494","journal-title":"Eur J Cancer"},{"key":"3683_CR13","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","volume":"20","author":"SS Bielack","year":"2002","unstructured":"Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776\u2013790","journal-title":"J Clin Oncol"},{"key":"3683_CR14","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/bcp.12690","volume":"80","author":"JH Martin","year":"2015","unstructured":"Martin JH, Phillips E, Thomas DM, Somogyi A (2015) Adding the \u2018medicines\u2019 back in personaolized medicine to improve cancer treatment outcomes. Br J Clin Pharmacol 80:929\u2013931","journal-title":"Br J Clin Pharmacol"},{"key":"3683_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrc3838","volume":"14","author":"M Kansara","year":"2014","unstructured":"Kansara M, Teng W, Smyth M, Thomas DM (2014) Translational Biology of osteosarcoma. Nat Rev Cancer 14:722\u2013735","journal-title":"Nat Rev Cancer"},{"key":"3683_CR16","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, Delattre O, Paulussen M, Picci P, Sundby Hall K, van den Berg H, Ladenstein R, Michon J, Hjorth L, Judson I, Luksch R, Bernstein ML, Marec-B\u00e9rard P, Brennan B, Craft AW, Womer RB, Juergens H, Oberlin O (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33:3036\u20133046","journal-title":"J Clin Oncol"},{"key":"3683_CR17","doi-asserted-by":"publisher","first-page":"e27033","DOI":"10.1002\/pbc.27033","volume":"30","author":"JM Kahn","year":"2018","unstructured":"Kahn JM, Kelly KM (2018) Adolescent and young adult Hodgkin lymphoma: raising the bar through collaborative science and multidisciplinary care. Pediatr Blood Cancer 30:e27033","journal-title":"Pediatr Blood Cancer"},{"key":"3683_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","volume":"57","author":"DA Gewirtz","year":"1999","unstructured":"Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727\u2013741","journal-title":"Biochem Pharmacol"},{"key":"3683_CR19","doi-asserted-by":"crossref","first-page":"15851","DOI":"10.1016\/S0021-9258(18)47666-1","volume":"262","author":"RJ Boucek","year":"1987","unstructured":"Boucek RJ, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 262:15851\u201315856","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"3683_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jchromb.2005.08.017","volume":"826","author":"CM Gilbert","year":"2005","unstructured":"Gilbert CM, McGeary RP, Filippich LJ, Norris RL, Charles BG (2005) Simultaneous liquid chromatographic determination of doxorubicin and its major metabolite doxorubicinol in parrot plasma. J Chromatogr B Anal Technol Biomed Life Sci 826(1\u20132):273\u2013276","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"3683_CR21","volume-title":"NONMEM\u2019s user\u2019s guides","author":"SSL Beal","year":"2009","unstructured":"Beal SSL, Boekmann A, Bauer RJ (2009) NONMEM\u2019s user\u2019s guides. ICON Development Solutions, Ellicott City"},{"issue":"2","key":"3683_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Pihlgren P, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming. Comput Methods Progr Biomed 75(2):85\u201394","journal-title":"Comput Methods Progr Biomed"},{"issue":"3","key":"3683_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Progr Biomed 79(3):241\u2013257","journal-title":"Comput Methods Progr Biomed"},{"key":"3683_CR24","unstructured":"http:\/\/www.pltsoft.com . Accessed 10 Sept 2018"},{"key":"3683_CR25","volume-title":"R: a language and environment for statistical computing","author":"R_Core_Team","year":"2014","unstructured":"R_Core_Team (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna"},{"issue":"3","key":"3683_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00280-013-2069-1","volume":"71","author":"NE Kontny","year":"2013","unstructured":"Kontny NE, Wurthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jorger M, Schellens JH, Hempel G (2013) Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Cancer Chemother Pharmacol 71(3):749\u2013763. https:\/\/doi.org\/10.1007\/s00280-013-2069-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"3683_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0272-4","author":"S Voller","year":"2015","unstructured":"Voller S, Boos J, Krischke M, Wurthwein G, Kontny NE, Boddy AV, Hempel G (2015) Age-dependent pharmacokinetics of doxorubicin in children with cancer. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-015-0272-4","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3683_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/mpo.10052","volume":"38","author":"BM Frost","year":"2002","unstructured":"Frost BM, Eksborg S, Bjork O, Abrahamsson J, Behrendtz M, Castor A, Forestier E, Lonnerholm G (2002) Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 38(5):329\u2013337. https:\/\/doi.org\/10.1002\/mpo.10052","journal-title":"Med Pediatr Oncol"},{"key":"3683_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00280-017-3309-6","volume":"80","author":"K Kunarajah","year":"2017","unstructured":"Kunarajah K, Hennig S, Norris RL, Lobb M, Charles BG, Pinkerton R, Moore AS (2017) Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?. Cancer Chemother Pharmacol 80:15\u201325","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"3683_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481\u2013504","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"3683_CR31","unstructured":"https:\/\/uupharmacometrics.github.io\/PsN\/docs.html . Accessed Aug 2018"},{"issue":"1","key":"3683_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","volume":"59","author":"J Parke","year":"1999","unstructured":"Parke J, Holford NH, Charles BG (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixedeffects population models. Comput Methods Progr Biomed 59(1):19\u201329","journal-title":"Comput Methods Progr Biomed"},{"key":"3683_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J 532 Pharmacokinet Pharmacodyn 28:481\u2013504","journal-title":"J 532 Pharmacokinet Pharmacodyn"},{"key":"3683_CR34","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/bcp.13070","volume":"82","author":"JS P\u00e9rez-Blanco","year":"2016","unstructured":"P\u00e9rez-Blanco JS, Santos-Buelga D, Fern\u00e1ndez De Gatta MDM et al (2016) Population pharmacokinetic of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin\u00b4s lymphoma. Br J Clin Pharmacol 82:1517\u20131527","journal-title":"Br J Clin Pharmacol"},{"key":"3683_CR35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00280-002-0542-3","volume":"51","author":"S Callies","year":"2003","unstructured":"Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L (2003) A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemother Pharmacol 51:107\u2013118","journal-title":"Cancer Chemother Pharmacol"},{"key":"3683_CR36","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1200\/JCO.2010.28.3473","volume":"28","author":"GJ Veal","year":"2010","unstructured":"Veal GJ, Hartford CM, Stewart CF (2010) Clinical pharmacology in the adolescent oncology patient. J Clin Oncol 28:4790\u20134799","journal-title":"J Clin Oncol"},{"key":"3683_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00685876","volume":"32","author":"BJ Cusack","year":"1993","unstructured":"Cusack BJ, Young SP, Driskell J, Olson RD (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32:53\u201358","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3683-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T02:03:27Z","timestamp":1661997807000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3683-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3683"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3683-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"31 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}